Myriad Genetics, Inc.: Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc. announced ...
AI and neural networks can reduce wait times for lesion classification in breast cancer patients
One of the most agonizing experiences a cancer patient suffers is waiting without knowing: waiting for a diagnosis, waiting ...
manilatimes1d
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor ...
EurekAlert!2d
ACC to host Cardio-oncology Conference in Washington and virtually
Taking place on February 14-16, 2025, in Washington, the American College of Cardiology (ACC) Advancing the Cardiovascular Care of the Oncology Patient conference is an interdisciplinary and ...
The American Journal of Managed Care2d
New Findings Strengthens Case for Exercise Therapy in Cancer Care
A new meta-analysis adds to the body of literature promoting the benefits of exercise for patients with cancer.
YPrime Releases Reimagined eCOA Automated Data Change Form for More Efficient Clinical Trial Data Management
A 2024 survey of eCOA professionals at sponsor organizations revealed that 50% of respondents identified eCOA Data Change ...
Latin Times3d
Deceased Alzheimer Patient Was Denied Coverage After Wrong Patients' Test Results Were 'Cut and Paste' in Her Assessment
An elderly Alzheimer's patient was denied coverage due to a botched assessment containing another patient's details, forcing her family to fight for six years to recover her life savings.
NHS 'cut and paste' wrong patient's details in Alzheimer's case
NHS 'cut and paste' wrong patient's details in Alzheimer's case - The NHS Lincolnshire Integrated Care Board has since ...